CNX Therapeutics Acquires Sativex from Jazz Pharmaceuticals
October 31, 2025
CNX Therapeutics has acquired the global Sativex (nabiximols) business from Jazz Pharmaceuticals, with the deal closing on 31 October 2025. The transaction includes marketing authorisations and commercial rights worldwide and the UK entity SVX Therapeutics Limited; Jazz will support a transition period under a Transition Service Agreement.
- Buyers
- CNX Therapeutics
- Targets
- Sativex (nabiximols) global business, SVX Therapeutics Limited
- Sellers
- Jazz Pharmaceuticals plc
- Industry
- Pharmaceuticals
- Location
- England, United Kingdom
- Transaction Type
- Divestiture
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.